University of Limerick Institutional Repository

Nanomedicine against Aβ aggregation by β–sheet breaker peptide delivery:In vitro evidence

DSpace Repository

Show simple item record

dc.contributor.author Pederzoli, Francesca
dc.contributor.author Ruozi, Barbara
dc.contributor.author Duskey, Jason T.
dc.contributor.author Hagmeyer, Simone
dc.contributor.author Sauer, Ann Katrin
dc.contributor.author Grabrucker, Stefanie
dc.contributor.author Coelho, Romina
dc.contributor.author Oddone, Natalia
dc.contributor.author Ottonelli, Ilaria
dc.contributor.author Daini, Eleonora
dc.contributor.author Zoli, Michele
dc.contributor.author Vandelli, Maria Angela
dc.contributor.author Tosi, Giovanni
dc.contributor.author Grabrucker, Andreas M.
dc.date.accessioned 2019-11-12T11:55:19Z
dc.date.available 2019-11-12T11:55:19Z
dc.date.issued 2019
dc.identifier.uri http://hdl.handle.net/10344/8221
dc.description peer-reviewed en_US
dc.description.abstract The accumulation of amyloid β (Aβ) triggers a cascade of toxic events in Alzheimer’s disease (AD). The KLVFF peptide can interfere with Aβ aggregation. However, the peptide suffers from poor bioavailability and the inability to cross the blood–brain barrier. In this work, we study the possibility of adopting nanomedicine to overcome KLVFF limits in biodistribution. We produced new engineered polymeric nanoparticles (NPs), and we evaluated the cellular toxicity of these NPs and validated that KVLFF peptides released by NPs show the same promising effects on AD pathology. Our results revealed the successful generation of KVLFF loaded NPs that, without significant effects on cell heath, are even more potent in reversing Aβ-induced pathologies compared to the free peptide. Therefore, NPs will significantly advance KVLFF treatment as a therapeutic option for AD. en_US
dc.language.iso eng en_US
dc.publisher MDPI en_US
dc.relation MEACI en_US
dc.relation.ispartofseries Pharmaceutics;11, 572
dc.subject Alzheimer’s disease en_US
dc.subject polymeric nanoparticles en_US
dc.subject KLVFF peptide en_US
dc.subject blood-brain barrier en_US
dc.title Nanomedicine against Aβ aggregation by β–sheet breaker peptide delivery:In vitro evidence en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.3390/pharmaceutics11110572
dc.contributor.sponsor UNIMORE en_US
dc.contributor.sponsor MEACI en_US
dc.contributor.sponsor Evangelisches Studienwerk Villigst e.V. en_US
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics